- Home
- NXTC vs LGVN Comparison
NXTC vs LGVN Comparison
Compare NXTC & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- LGVN
- Stock Information
- Founded
- NXTC 2015
- LGVN 2014
- Country
- NXTC United States
- LGVN United States
- Employees
- NXTC N/A
- LGVN N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- NXTC Health Care
- LGVN Health Care
- Exchange
- NXTC Nasdaq
- LGVN Nasdaq
- Market Cap
- NXTC 23.0M
- LGVN 26.0M
- IPO Year
- NXTC 2019
- LGVN 2021
- Fundamental
- Price
- NXTC $0.79
- LGVN $1.70
- Analyst Decision
- NXTC Strong Buy
- LGVN Strong Buy
- Analyst Count
- NXTC 2
- LGVN 3
- Target Price
- NXTC $4.00
- LGVN $8.67
- AVG Volume (30 Days)
- NXTC 201.3K
- LGVN 314.6K
- Earning Date
- NXTC 11-07-2024
- LGVN 02-25-2025
- Dividend Yield
- NXTC N/A
- LGVN N/A
- EPS Growth
- NXTC N/A
- LGVN N/A
- EPS
- NXTC N/A
- LGVN N/A
- Revenue
- NXTC N/A
- LGVN $1,852,000.00
- Revenue This Year
- NXTC N/A
- LGVN $208.32
- Revenue Next Year
- NXTC N/A
- LGVN $43.96
- P/E Ratio
- NXTC N/A
- LGVN N/A
- Revenue Growth
- NXTC N/A
- LGVN 141.46
- 52 Week Low
- NXTC $0.76
- LGVN $0.77
- 52 Week High
- NXTC $2.57
- LGVN $10.30
- Technical
- Relative Strength Index (RSI)
- NXTC 36.33
- LGVN 41.48
- Support Level
- NXTC $0.76
- LGVN $1.72
- Resistance Level
- NXTC $0.83
- LGVN $1.89
- Average True Range (ATR)
- NXTC 0.07
- LGVN 0.14
- MACD
- NXTC 0.01
- LGVN -0.00
- Stochastic Oscillator
- NXTC 14.87
- LGVN 8.47
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.